Munich Cancer Registry



- ▶ Baseline statistics
- ▶ Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

C64: Kidney cancer

Year of diagnosis	1978-1987	1988-1997	1998-2011
Patients	827	2,772	7,862
Diseases	830	2,803	8,010
Creation date	04/01/2013		
Export date	01/03/2013		
Population	4.5 m		



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C64__E.pdf




Figure 1a. Relative survival of patients with kidney cancer by period of diagnosis. Included in the evaluation are 6,936 cases diagnosed between 1978 and 2011.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.



2 77.3 80.3 80.8 84.8 81.6 89 3 71.3 75.6 76.0 81.8 76.7 82 4 67.2 72.8 72.0 79.4 73.3 80 5 64.5 71.2 68.4 77.4 69.1 77 6 62.3 70.4 64.7 75.1 65.8 70 7 59.5 68.6 61.0 72.7 63.3 79	Period of diagnosis											
Years obs. % rel. % obs. % rel. % obs. % rel. % 0 100.0 100.0 100.0 100.0 100.0 100.0 1 85.8 87.5 88.4 90.6 87.2 89.2 2 77.3 80.3 80.8 84.8 81.6 89.3 3 71.3 75.6 76.0 81.8 76.7 89.3 4 67.2 72.8 72.0 79.4 73.3 80.3 5 64.5 71.2 68.4 77.4 69.1 77.3 6 62.3 70.4 64.7 75.1 65.8 70.2 7 59.5 68.6 61.0 72.7 63.3 75.2												
0 100.0 100	n=3,881											
1 85.8 87.5 88.4 90.6 87.2 88 2 77.3 80.3 80.8 84.8 81.6 88 3 71.3 75.6 76.0 81.8 76.7 82 4 67.2 72.8 72.0 79.4 73.3 80 5 64.5 71.2 68.4 77.4 69.1 73 6 62.3 70.4 64.7 75.1 65.8 70 7 59.5 68.6 61.0 72.7 63.3 78	%											
2 77.3 80.3 80.8 84.8 81.6 85 3 71.3 75.6 76.0 81.8 76.7 82 4 67.2 72.8 72.0 79.4 73.3 80 5 64.5 71.2 68.4 77.4 69.1 73 6 62.3 70.4 64.7 75.1 65.8 76 7 59.5 68.6 61.0 72.7 63.3 75	0.0											
3 71.3 75.6 76.0 81.8 76.7 82 4 67.2 72.8 72.0 79.4 73.3 80 5 64.5 71.2 68.4 77.4 69.1 75 6 62.3 70.4 64.7 75.1 65.8 76 7 59.5 68.6 61.0 72.7 63.3 75	9.3											
4 67.2 72.8 72.0 79.4 73.3 80 5 64.5 71.2 68.4 77.4 69.1 73.3 6 62.3 70.4 64.7 75.1 65.8 76 7 59.5 68.6 61.0 72.7 63.3 78	5.5											
5 64.5 71.2 68.4 77.4 69.1 75 6 62.3 70.4 64.7 75.1 65.8 76 7 59.5 68.6 61.0 72.7 63.3 75	2.3											
6 62.3 70.4 64.7 75.1 65.8 76 7 59.5 68.6 61.0 72.7 63.3 75	0.6											
7 59.5 68.6 61.0 72.7 63.3 75	7.8											
	6.6											
0 550 664 500 744 604 7	5.0											
8 55.9 66.1 58.2 71.1 60.1 73	3.1											
9 54.3 65.6 55.3 69.4 57.8 72	2.3											
10 51.6 63.9 52.5 67.6 55.8 7	1.7											
11 49.3 62.5 49.7 65.7 53.9 7	1.1											
12 46.4 60.1 46.6 63.4 52.8 7°	1.1											
13 43.6 58.4 43.9 61.5 50.4 69	9.6											
14 42.2 57.8 41.4 59.6												
15 39.3 55.3 38.4 56.8												
16 37.1 53.8 36.4 55.6												
17 33.8 50.3 34.6 54.4												
18 30.9 47.2 33.8 54.4												
19 28.9 45.2 32.0 53.3												
20 26.6 42.8 29.0 50.3												

Table 1b. Observed (obs.) and relative (rel.) survival of patients with kidney cancer by period of diagnosis for period 1978-2011 (N=6,936).




Figure 2a. Survival of patients with kidney cancer by gender. Included in the evaluation are 6,226 cases diagnosed between 1988 and 2011.

Munich Cancer Registry 04/01/2013 surv_C64__E.pdf

Gender												
	Ma	ale	Fem	nale								
	n=3,	925	n=2,301									
Years	obs. %	rel. %	obs. %	rel. %								
0	100.0	100.0	100.0	100.0								
1	87.7	90.0	87.5	89.4								
2	81.2	85.4	81.3	84.9								
3	76.4	82.4	76.4	81.5								
4	72.6	80.4	72.9	79.4								
5	68.4	77.7	69.6	77.6								
6	64.6	75.4	66.5	75.8								
7	61.5	73.9	63.1	73.6								
8	58.3	71.8	60.5	72.1								
9	55.7	70.7	57.7	70.6								
10	53.0	69.3	55.0	68.8								
11	50.3	67.6	52.5	67.3								
12	46.9	64.9	50.6	66.7								
13	44.2	63.0	47.9	64.8								
14	41.6	61.2	45.6	63.2								
15	38.9	59.0	41.8	59.5								
16	36.9	57.8	39.8	58.0								
17	34.6	55.9	38.5	57.4								
18	33.8	55.7	37.3	57.4								
19	31.4	54.1	36.2	57.4								
20	28.9	51.9	32.2	53.0								

Table 2b. Observed (obs.) and relative (rel.) survival of patients with kidney cancer by gender for period 1988-2011 (N=6,226).




Figure 3a. Relative survival of patients with kidney cancer by age category. Included in the evaluation are 6,226 cases diagnosed between 1988 and 2011.

Munich Cancer Registry 04/01/2013 surv_C64__E.pdf




Figure 3b. Observed survival of patients with kidney cancer by age category. Included in the evaluation are 6,226 cases diagnosed between 1988 and 2011.

Age category											
	0-49	yrs	50-59	9 yrs	60-69 yrs 70-79 yrs			9 yrs	80+ yrs		
	n=8	317	n=1,	354	n=2,	002	n=1,	580	n=4	173	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	94.9	95.1	91.0	91.6	88.3	89.7	84.3	87.6	73.8	80.9	
2	90.5	91.0	86.1	87.4	82.4	85.2	76.3	82.7	62.2	76.0	
3	88.6	89.2	83.1	85.1	77.5	81.5	69.7	79.0	53.7	73.6	
4	86.5	87.4	80.3	82.9	74.0	79.4	64.9	77.1	46.7	72.1	
5	85.1	86.2	78.1	81.5	70.2	76.9	60.0	75.4	36.1	63.0	
6	82.9	84.2	75.0	79.1	66.8	74.8	55.9	74.0	29.7	59.1	
7	81.2	82.8	72.7	77.4	64.8	74.5	49.5	70.4	25.7	58.4	
8	80.0	82.0	70.7	76.2	61.5	72.6	45.4	69.0	20.8	55.9	
9	78.0	80.2	67.7	74.1	59.3	72.1	41.8	68.6	18.4	55.9	
10	77.2	79.7	66.0	72.9	56.1	70.4	38.4	67.9	12.8	48.7	
11	75.9	78.8	64.5	72.4	52.8	68.5	34.6	66.3	9.4	45.1	
12	74.5	77.6	61.8	70.5	49.9	67.0	30.5	65.3			
13	73.4	77.0	59.7	69.2	46.9	65.8	25.8	60.5			
14	72.9	76.9	57.0	67.2	44.4	65.0	21.3	56.3			
15	71.4	75.6	54.2	65.0	40.4	62.4	16.8	50.1			
16	70.2	75.0	52.3	64.2	37.6	60.5	14.7	48.6			
17	68.7	74.1	50.9	63.7	34.6	59.2	13.4	48.6			
18	68.7	73.8	49.3	62.9	33.4	59.2	12.8	48.6			
19	67.6	73.3	47.8	62.3	30.7	59.2					
20	67.6	72.8	47.0	62.3	24.1	50.8					

Table 3c. Observed (obs.) and relative (rel.) survival of patients with kidney cancer by age category for period 1988-2011 (N=6,226).




Figure 4a. Relative survival of patients with kidney cancer by UICC. For 3,788 of 3,881 cases diagnosed between 1998 and 2011 valid data could be obtained for this item. For a total of 3,775 cases an evaluable classification was established. The grey line represents the subgroup of 106 patients with missing values regarding UICC (2.7% of 3,881 patients, the percent values of all other categories are related to n=3,775).

UICC											
		I		- 1	l	ll ll	l	1\	/	NA/NOS	
		n=2,	155	n=3	340	n=7	n=724		n=556		106
	Years	obs. %	rel. %								
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	97.9	99.9	94.3	96.5	85.9	88.2	43.9	45.0	79.0	81.9
	2	95.8	99.7	87.7	92.0	77.0	81.4	30.0	31.5	68.3	73.7
	3	93.4	99.4	82.7	88.7	68.7	74.7	21.7	23.2	54.5	61.5
	4	90.6	98.7	79.5	87.6	65.5	73.0	16.4	17.9	46.7	54.3
	5	86.6	96.6	76.6	86.4	59.9	68.7	12.7	14.2	42.2	49.7
	6	84.4	96.5	69.8	80.5	53.7	63.5	12.1	13.5	32.7	40.1
	7	81.8	95.9	65.7	77.9	52.6	63.4	10.7	12.4		
	8	78.6	94.6	63.1	76.8	47.4	59.2				
	9	75.7	93.6	60.8	76.2	46.7	60.3				
	10	73.9	93.9	57.6	74.3	44.4	58.9				

Table 4b. Observed (obs.) and relative (rel.) survival of patients with kidney cancer by UICC for period 1998-2011 (N=3,775).




Figure 4c. Conditional relative 5-year survival of patients with kidney cancer by UICC. For 6,006 of 6,226 cases diagnosed between 1988 and 2011 valid data could be obtained for this item. For a total of 5,982 cases an evaluable classification was established. The grey line represents the subgroup of 244 patients with missing values regarding UICC (3.9% of 6,226 patients, the percent values of all other categories are related to n=5,982).

					UICC						
	1		II		II.	l	I۷	′	NA/N	NOS	
		Cond.		Cond.		Cond.		Cond.		Cond.	
		surv. %		surv. %		surv. %		surv. %		surv. %	
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs	
0	2,374	96.5	1,447	91.2	1,339	69.1	822	14.8	244	71.3	
1	2,173	96.7	1,370	89.8	1,107	74.3	349	28.7	204	75.6	
2	1,908	96.1	1,266	90.7	915	78.6	211	36.8	179	78.5	
3	1,633	95.1	1,179	91.7	773	80.1	136	46.6	157	81.5	
4	1,370	95.0	1,105	91.8	683	80.8	100	47.8	142	86.5	
5	1,137	97.1	1,023	91.1	574	83.1	74	51.6	129	87.7	
6	942	96.1	950	92.7	497	84.8			112	86.1	
7	791	98.0	884	92.6	438	82.9			104	85.5	
8	645	98.3	841	90.0	379	85.7			94	90.3	
9	493	100.1	787	88.6	332	85.7			92	87.9	
10	368	100.7	725	87.7	298	82.1			85	79.9	

Table 4d. Conditional relative 5-year survival of patients with kidney cancer by UICC for period 1988-2011 (N=5,982).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup UICC="I", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 95.1% (n=1,633).




Figure 4e. Relative survival of patients with kidney cancer by TNM staging. For 3,788 of 3,881 cases diagnosed between 1998 and 2011 valid data could be obtained for this item. For a total of 3,785 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 96 patients with missing values regarding TNM staging (2.5% of 3,881 patients, the percent values of all other categories are related to n=3,785).

	TNM staging													
	T11	M0	T2	M0	T3I	M0	NO	MO	N+	M0	NX	M0	M	11
	n=1,	046	n=1	173	n=3	307	n=1,	042	n=	49	n=2	277	n=5	540
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.9	99.9	94.1	96.0	91.3	93.8	97.5	99.5	64.5	66.1	96.0	98.0	43.7	44.8
2	95.6	99.6	85.2	89.4	83.2	87.8	94.0	98.1	49.0	49.2	90.2	94.1	29.8	31.3
3	93.6	99.5	78.4	83.9	72.4	78.4	89.8	95.8	39.4	41.2	86.6	92.3	21.2	22.7
4	91.4	99.4	75.6	83.4	68.6	75.7	87.0	95.0			83.7	91.2	15.7	17.1
5	88.2	98.1	74.0	83.4	63.4	71.9	83.9	93.6			79.2	88.2	12.0	13.3
6	86.1	97.9	69.9	81.2	57.4	66.9	81.2	93.0			74.8	85.0	11.3	12.5
7	82.9	96.8	66.5	78.9	55.9	66.2	78.1	91.7			71.4	82.6	9.9	11.4
8	79.9	95.5	62.7	76.3	47.1	58.1	73.8	88.9			67.6	80.2	9.4	10.3
9	76.6	94.0	61.1	76.4	47.1	58.9	71.1	87.9			66.3	80.7		
10	74.3	93.5	58.6	75.8	44.4	58.0	68.5	87.2			64.8	79.4		

TNM staging													
cont'd	M	X	NA/N	NOS									
	n=1,	699	n=	96									
Years	obs. %	rel. %	obs. %	rel. %									
0	100.0	100.0	100.0	100.0									
1	93.5	95.6	76.9	79.9									
2	89.6	93.8	65.0	70.5									
3	86.0	92.3	50.9	57.8									
4	82.8	91.0	45.2	52.3									
5	77.7	87.5	40.3	47.9									
6	73.6	85.1											
7	71.5	85.0											
8	68.7	84.1											
9	66.5	84.0											
10	65.0	84.3											

Table 4f. Observed (obs.) and relative (rel.) survival of patients with kidney cancer by TNM staging for period 1998-2011 (N=5,133).




Figure 5a. Observed post-progression survival of 1,784 patients with kidney cancer diagnosed between 1978 and 2011 (incl. M1). These 1,784 patients with documented progression events during their course of disease represent 25.7% of the totally 6,936 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=254, 3.7%). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

Type of progression										
	All types	Distant metastasis								
	n=1,784	n=1,699								
Months	%	%								
0	100.0	100.0								
12	52.9	52.4								
24	36.7	35.7								
36	27.1	26.2								
48	21.4	20.6								
60	17.8	17.0								

Table 5b. Observed post-progression survival of patients with kidney cancer for period 1978-2011 (N=1,784).



Shortcuts

AS Assembled survival chart (observed, expected, relative)

CS Conditional survival

DCO Death certificate only. The death certificate provides the only notification to the registry.

MCR Munich Cancer Registry, Germany (Tumorregister München)

NA Not available

NCI National Cancer Institute, USA

NOS Not otherwise specified

OS Observed/overall survival (Kaplan-Meier estimate)

PPS Post-progression survival

RS Relative Survival. Ratio of observed and expected survival (derived from the normal population)

SEER Surveillance, Epidemiology, and End Results, USA

TTP Time to progression

Date of entry: Date of diagnosis

Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified

recurrence

First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate).

First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where

applicable ("reverse" Kaplan-Meier estimate).

UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C64: Kidney cancer [Internet]. 2013 [updated 2013 Apr 1; cited 2013 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C64__E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

F	ig./Tbl	l.	Page
	1a	Relative survival by period of diagnosis (chart)	2
	1b	Survival by period of diagnosis (table)	3
	2a	Survival by gender (chart)	3
	2b	Survival by gender (table)	4
	3a	Relative survival by age category (chart)	4
	3b	Observed survival by age category (chart)	5
	3c	Survival by age category (table)	5
	4a	Relative survival by UICC (chart)	6
	4b	Survival by UICC (table)	6
	4c	Conditional survival by UICC (chart)	7
	4d	Conditional survival by UICC (table)	7
	4e	Relative survival by TNM staging (chart)	8
	4f	Survival by TNM staging (table)	8
	5a	Observed post-progression survival (chart)	9
	5b	Observed post-progression survival (table)	10

